US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC).

Pfizer reckons it will make a whopping $22 ... run out of money and had stopped accepting new doses as it needs a cash injection of $5.2 billion to keep operating. "Pfizer…has made more than ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual ...

Pfizer is stopping development of its experimental ... GLP-1 drugs can cause substantial weight loss, but they are delivered by injection, making them more difficult to manufacture.

Pfizer's danuglipron promotes weight loss by targeting GLP-1, which is also how Novo Nordisk's weight loss injection Wegovy and diabetes treatment Ozempic work. Eli Lilly's weight loss injection ...

Pfizer has reported that its anti-tissue factor ... working as well as clotting factor replacement with a simple 150 mg injection given once a week. In the phase 3 BASIS trial, the drug achieved ...